HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Consumer Spending On Supplements Helps Trim Chronic Disease Treatment Costs – CRN Study

Executive Summary

CRN study on health-care cost savings from use of supplements offers data on reductions in spending on hospitalizations for chronic conditions linked to use of omega-3s, fiber and other supplements as well as on efficacy of certain dietary ingredients in helping prevent chronic conditions.

You may also be interested in...



HBW US Market News: Awards, Appointments, Actions And Nutrition And Disaster Relief

Kochanowski retires with CHPA Career Achievement award; Haelon’s Paley chairs CHPA board; House Oversight Committee chair, FTC commissioner speak at NCPA Fly-In; NasoClenz provided to help consumers following East Palestine disaster; CRN’s Mister attends White House End Hunger launch.

HBW News: CRN Expands Staff, Sami-Sabinsa CEO Dies, GOED Database Study Published

Sami-Sabinsa announces death of CEO Nair; government affairs director, scientific/regulatory affairs manager, membership associate join CRN; and GOED launches database with more than 45,000 EPA, DHA studies.

Supplement Health Care Cost Savings Movement Faces Long Road

A CRN-funded report says specific supplement regimens could save the health care system billions, but the path to creating and funding dietary supplement programs for disease prevention is fraught with obstacles, including additional costs, political controversy and reticence to change by firms and insurers, experts say.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS152881

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel